You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Treatment of Inflammatory Complications of Respiratory Infection
SBC: Respana Therapeutics, Inc Topic: NIAIDAbstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Programming Metabolically Fit TILs for Immunotherapy
SBC: LIPO-IMMUNO TECH LLC Topic: NCIABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SIRPant Technology for anti-Cancer Immunity
SBC: SIRPANT IMMUNOTHERAPEUTICS INC Topic: 102PROJECT SUMMARY Immune evasion is a hallmark of cancer. Various tumor immunotherapy treatments, such as immune checkpointblockade and cancer vaccination, have been developed to overcome cancer’s ability to avoid immune detectionand destruction; however, the result of these endeavors have not been satisfactory given a number of criticalbarriers. One of these barriers, and a prominent mechanism by ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
SBC: Trevarx Biomedical, Inc. Topic: 102ABSTRACT: Poly (ADP-ribose) polymerase inhibitors (PARPi’s) have emerged as important therapeutic agents targeting a broadening class of gene mutations approved for treatment of breast, ovarian, prostate, and other cancers. Genomic assays of BRCA-related genes and tumor homologous repair deficiency are used as companion diagnostics for PARPi therapy but have imperfect predictive efficacy for PAR ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Zero Trust Methodology for Digital Modeling
SBC: ISTARI, INC. Topic: X22DOTCSO1At a high level, the major mission focus of this research is: How can the DAF and broader DoD leverage Zero Trust methodology into digital model sharing and collaboration? The technical focus of this research is: What is the best manner to link digital
STTR Phase II 2023 Department of DefenseAir Force -
Information Extraction for New Emerging Noisy User-generated Microtext
SBC: INTUIDEX INC Topic: AF19BT006This proposal presents an opportunity to address many challenges of information extraction and related techniques when applied to noisy user-generated microtext in PAI (publicly available information) and military “chat” data, in support of United States Air Force and Air National Guard intelligence analysts leveraging such sources in their missions. Given the breadth of chat data platforms ...
STTR Phase II 2022 Department of DefenseAir Force -
Sense and Avoid Autonomy Capabilities Enabling Orbs
SBC: NEAR EARTH AUTONOMY, INC Topic: AFX20DTCSO1A critical capability needed by unmanned aircraft systems (UAS), both in military and in commercial use, is to sense and avoid other aircraft. Such a capability constitutes a last line of safety when air traffic control is unable to keep aircraft away from each other. This is partly because UAS cannot practically be constrained to assigned corridors but also because these aircraft must fit into cu ...
STTR Phase II 2022 Department of DefenseAir Force -
A novel PEDF peptide mimetic for diabetic retinopathy
SBC: SKYRAN BIOLOGICS, INC. Topic: NEIAbstract The overall goal of Skyran Biologics is to develop a potent topical therapeutic for diabetic retinopathy (DR), a leading cause of vision loss globally. Our research team identified Pigment Epithelium-Derived Factor (PEDF) and showed it is expressed in the eye and provides significant protection to the injured retina. Since its discovery, we identified a 44-mer N-terminus bioactive region ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIAIDABSTRACT Infection of the eye by Herpes Simplex Virus-1 (HSV-1) can result in Herpes Keratitis (HK), which is the leading cause of infectious corneal blindness worldwide. In the U.S., nearly 500,000 individuals experience ocular herpes infections that are often recurrent and culminate in progressive corneal scarring and loss of vision. The gold standard treatment is Acyclovir (ACV) that targets HS ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Rehabilitation Using Community-Based Affordable Robotic Exercise Systems (Rehab CARES)
SBC: Recupero Robotics LLC Topic: NICHDPROJECT SUMMARY Stroke is the leading cause of serious long-term disability. It is estimated that 5.8–6.5 million people currently live with stroke related disability in the US and that this number will increase by 20.5% by 2030. The current US health infrastructure is not prepared for these increasing numbers. Limitations in health insurance coverage and the shortage of rehabilitation practitio ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health